Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infimab, Infliximab biosimilar, BOW-015 + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rheumatoid Arthritis | India | - | - |
Phase 3 | 68 | jncnrbmjnb(ysrzvjjgro) = sswbowaclw zyikpkjcjk (cbupkjnmwq ) View more | Positive | 14 Jun 2017 | |||
Phase 1 | - | - | ssnmchyvgs(yppiglzwvp) = scluqijdqz rezwbsxkpb (sqhraovwvl ) | - | 10 Jun 2015 | ||
Reference infliximab (rIFX) | ssnmchyvgs(yppiglzwvp) = mlhgrtcpza rezwbsxkpb (sqhraovwvl ) | ||||||
Phase 3 | 189 | nnvvyysblp(vltblbyxif) = qiinhgcnjd jseyguyjsk (zgdfzfnuiw ) View more | Positive | 11 Jun 2014 | |||
Innovator IFX (iIFX) | nnvvyysblp(vltblbyxif) = hyrdupgvkn jseyguyjsk (zgdfzfnuiw ) View more |